MEDIWOUND LTD (MDWD)
Health Care · Wound care biopharmaceuticals · NASDAQ
MediWound develops enzymatic biotherapies that debride wounds and burns by removing dead tissue, targeting faster healing with biological precision.
What MEDIWOUND LTD does
MediWound Ltd is a biopharmaceutical company specializing in enzymatic wound care products derived from proteolytic enzymes. The company develops and commercializes therapies designed to debride necrotic (dead) tissue from wounds and burns. MediWound's primary focus is on bringing innovative, biologically-derived treatments to the wound care market to accelerate healing and improve patient outcomes.
Themes: wound care, enzymatic therapeutics, tissue regeneration, acute care
Fundamentals
- Price$13.21 as of 2026-08-21 close
- Market cap$174M as of 2026-08-24
- 1-year return-24.0% 2025-08-21 close $17.39 → 2026-08-21 close $13.21
- P/En/a negative earnings
- Net margin-180.3% as of 2026-08-24
- Gross margin+19.6% as of 2026-08-24
- ROE-67.2% as of 2026-08-24
- Debt / equity0.20 as of 2026-08-24
- Revenue growth (YoY)-24.6% as of 2026-08-24
- Revenue CAGR (3y)-13.8% SEC XBRL
- Beta0.09 as of 2026-08-24
- Last reported earningsn/a no confirmed date — as a foreign private issuer it reports on Form 6-K, which carries no earnings item code
How MDWD compares in its sector
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginbottom 10% 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How MEDIWOUND LTD looks technically
MEDIWOUND LTD (MDWD) is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed below its 200-day average about 229 trading days ago — a "death cross", a bearish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative). It made a new 20-day low about 2 trading days ago. It is 1.1% above its 52-week low (its lowest price of the past year).
Trend
8
| Distance from the 200-day | it is trading 20.2% below its 200-day average, the long-term trend line — a long-term downtrend | -20.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $14.25 | $14.25 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $16.55 | $16.55 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing low 21 calendar days ago — the swings before that are what the structure reading is measured on | 21 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in the fourth leg, a pullback against that downward direction; the labelling fails if price closes above 13.99. It is the only labelling that fits, though not with textbook proportions, and it describes the swings already printed, not what comes next. | possible downward five-wave sequence, in wave 4 (atypical proportions) |
| Since the 50/200 cross | its 50-day average crossed below its 200-day average about 229 trading days ago — a "death cross", a bearish long-term signal | 229 sessions |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 10, below the 25 that marks a real trend) | 10.0 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 35, neither overbought (above 70) nor oversold (below 30) | 34.8 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($13.06 to $14.58) — its "stochastic" reading is 10 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 9.9 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 10 trading days ago (its momentum flipped negative) | 10 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $20.30 | $20.30 |
|---|---|---|
| From the 52-week high | it is 34.9% below its 52-week high (its highest price of the past year) | -34.9% |
| Above the 52-week low | it is 1.1% above its 52-week low (its lowest price of the past year) | +1.1% |
| Below the 52-week high | it is 34.9% below its highest point of the past year | 34.9% |
| Since a 20-day breakout | it made a new 20-day low about 2 trading days ago | 2 sessions |
| Since a 55-day breakout | it made a new 55-day low about 2 trading days ago | 2 sessions |
| All-time high | its highest closing price on record is $135.03 (set on 2014-03-21) | $135.03 |
| Given back of the 52-week move | over the past year its closes ranged ($13.12 to $19.69), and it has recovered essentially none of its fall from last year’s high — 1% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $17.18 to $17.39. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 1.4% |
| From the all-time high | it is 90.2% below its all-time high | -90.2% |
| Nearest price level | it is trading 5.1% below a resistance level at $13.88 — a price it turned at three times since 2026-06-16, most recently on 2026-07-31. Since 2024-08-21 it has 0 such levels below the current price and 13 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +5.1% |
| All-time low | its lowest closing price on record is $7.10 (set on 2023-09-08) | $7.10 |
| Above the all-time low | it is 86.1% above its all-time low | +86.1% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 66th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $0.4426 between its high and its low — about 3.4% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $0.4426 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $13.09 and $14.78 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $13.09 – $13.94 – $14.78 |
| Typical daily range (% of price) | its price moves about 3.4% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.4% |
| Stretch from the 200-day average | it is trading 7.6 daily ranges below its 200-day average price (20.2% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 7.6 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.21× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.1% since the prior reading | -1.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
1
| Since a bearish engulfing | 9 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 9 sessions ago |
|---|
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.3% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.3% |
|---|---|---|
| Open gap | it gapped 5.3% below the previous close 58 sessions ago and has not traded back through the level it left behind at 16.68 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | -5.3% |
| Gap filled | a 3.3% gap up opened on 2026-07-31 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 9.8 percentage points (the stock lost 7.5% while the market gained 2.3%) | -9.8% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 24.7 percentage points (the stock lost 21.6% while the market gained 3.1%) | -24.6% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 37.1 percentage points (the stock lost 26.1% while the market gained 11.1%) | -37.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 44.5 percentage points (the stock lost 24.0% while the market gained 20.5%) | -44.5% |
Signal agreement
2
| Bullish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bullish state: near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 1 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: a "death cross" — its 50-day average is below its 200-day, trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 9.4% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is moderate, spanning 7.3% of the share price. | -9.4% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 18% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $16.15 — a volume-weighted average of daily closes over 158 sessions, not a true tick-by-tick VWAP. | -18.2% |
|---|
Price levels it has turned at before
MDWD last closed at $13.21 on 2026-08-21. Since 2024-08-21 it has turned at 0 prices below its last close and 13 above; the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $13.88 | Resistance | 5.1% above the last close | turned there three times · 2026-06-16 to 2026-07-31 |
| $14.92 | Resistance | 12.9% above the last close | turned there three times · 2026-03-30 to 2026-07-28 |
| $15.46 | Resistance | 17.0% above the last close | turned there twice · 2024-11-18 to 2026-06-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 4 of five, a pullback against that direction.
This labelling fails — stops being a possible reading at all — if it closes above $13.99.
It is the only labelling that fits these swings, though its proportions are not the textbook ones.
On past moves of this shape the leg has usually ended somewhere between $13.99 and $14.14 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Near the 52-week low · Pulled back from the 12-month high · Broke down to a new 20-day low · trendless / choppy (low ADX) · Analyst price target recently CUT | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.17 mean, 1=Strong Buy…5=Strong Sell) — 6 analysts
- Mean price target$29.83 range $22.00 – $36.00; median $30.00
Analyst estimates, as of 2026-08-22. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for MDWD
- Consensus EPS estimate-$0.726 next reporting period, as of 2026-08-22
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Pre-commercial or early-stage revenue with significant operating losses and negative net margins","Heavy dependence on regulatory approvals and clinical adoption in a competitive wound care market","Substantial revenue decline year-over-year, indicating market traction or product challenges"]
Insider activity (SEC Form 4)
6 open-market purchases and 0 open-market sales by insiders in the last 90 days.
- Last 90 days6 buys ($136046) · 0 sells — 3 buying insiders
- Last 180 days6 buys ($136046) · 0 sells — 3 buying insiders
Cluster buying: 3 different insiders reported open-market purchases (SEC code P) of MDWD within a 30-day window between 2026-05-29 and 2026-06-03. Disclosed Form 4 activity, not a prediction of performance or a buy signal.
Activity heuristic: net buying (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-06-03. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about MDWD's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
MDWD had 1,612,427 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for MDWD because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 1,612,427
- Prior settlement (shares) 1,616,406
- Reported change -0.25%
- Days to cover (reported) 24.22
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare MDWD vs…
Frequently asked questions
What does MEDIWOUND LTD (MDWD) do?
MediWound Ltd is a biopharmaceutical company specializing in enzymatic wound care products derived from proteolytic enzymes. The company develops and commercializes therapies designed to debride necrotic (dead) tissue from wounds and burns. MediWound's primary focus is on bringing innovative, biologically-derived treatments to the wound care market to accelerate healing and improve patient outcomes.
What sector is MEDIWOUND LTD (MDWD) in?
MEDIWOUND LTD (MDWD) is classified in the Health Care sector. Its industry is Wound care biopharmaceuticals. It trades on NASDAQ.
Who are MEDIWOUND LTD's (MDWD) competitors?
Notable peers of MEDIWOUND LTD (MDWD) include Vericel, Smith & Nephew, Integra LifeSciences, Organogenesis and MiMedx. This peer set is informational only — not financial advice.
Is MEDIWOUND LTD (MDWD) overbought or oversold right now?
MEDIWOUND LTD (MDWD) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 35, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on MDWD come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.